CEL-SCI Co. (NYSEAMERICAN:CVM) shares traded up 5.2% on Tuesday . The stock traded as high as $7.65 and last traded at $7.64, 544,550 shares traded hands during trading. A decline of 23% from the average session volume of 711,759 shares. The stock had previously closed at $7.26.
CEL-SCI (NYSEAMERICAN:CVM) last posted its earnings results on Tuesday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.10 million.
Institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its stake in CEL-SCI by 5.0% in the 4th quarter. BlackRock Inc. now owns 634,031 shares of the company’s stock valued at $1,820,000 after buying an additional 30,117 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in CEL-SCI in the 4th quarter valued at about $38,000. Thoroughbred Financial Services LLC lifted its stake in CEL-SCI by 21.1% in the 1st quarter. Thoroughbred Financial Services LLC now owns 13,921 shares of the company’s stock valued at $49,000 after buying an additional 2,428 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in CEL-SCI in the 1st quarter valued at about $42,000. Finally, Wells Fargo & Company MN lifted its stake in CEL-SCI by 1,924.1% in the 2nd quarter. Wells Fargo & Company MN now owns 28,965 shares of the company’s stock valued at $243,000 after buying an additional 27,534 shares in the last quarter.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
Recommended Story: How Does the Quiet Period Work?
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.